As a pivotal surface marker present on T cells, The CD3 antigen plays a crucial role in T cell activation, proliferation, and other essential processes, rendering it a highly favored target for bispecific antibodies. GemPharmatech developed the BALB/c-hCD3EDG model carrying human CD3E, CD3D, CD3G and mouse Cd3e, Cd3d, Cd3g removed. The BALB/c-hCD3EDG mice successfully express human CD3E/CD3D/CD3G on the T cell surface and exhibit a normal immune system.
【Case Study: Preclinical in vivo efficacy evaluation of anti-CD3/CD20 BsAb 】
BALB/c-hCD3EDG mice (6-8weeks) were subcutaneously inoculated with murine lymphoma cell line A20-hCD20 cells. Mice were randomly grouped when the average tumor volume reached 90mm3 and divided into a vehicle group and an anti-hCD3/hCD20 (Mosunetuzumab analogue) treated group (n=6). The test article was administered twice every week for a total of 6 times.
Treatment of anti-hCD3/hCD20 showed significant tumor growth inhibition (TGI=81.46%, left). Mice from both groups showed overall good health as shown by their body weight (right). The results demonstrated that BALB/c-hCD3EDG mice are an excellent model for assessing the in vivo efficacy of human CD3-bispecific antibodies.
【Resources of TAA-humanized mice for toxicity research 】
GemPharmatech has an extensive collection of syngeneic cell lines, including murine-derived cells and genetic modification of the corresponding cells.